AzTrials
AzTrials

Urgency Urinary IncontinencePhase 4NCT04227184

Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence

A Phase 4 study testing Trospium in people with Urgency Urinary Incontinence, run by Becky Clarkson at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This is a randomized double-blind crossover trial of trospium and placebo in women with urgency urinary incontinence, with evaluation (history, physical, incontinence evaluation and brain MRI) at baseline, and after each course of therapy. Read more about this study

Who is it for?
Ages 60 years and older, women only
Conditions the study is for
Urgency Urinary Incontinence
What is being tested?
Trospium
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
168 participants
Where
1 siteUnited States
Study dates
13 Feb 2020to 30 Oct 2025
Phase
Phase 4

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 60+ years old
  • Has UUI or urge-predominant mixed incontinence at least 5 times/ week for > 3 months despite treatment for reversible causes

Who cannot join

  • conditions/medications contraindicating trospium
  • If currently taking anticholinergic medications (participant must refrain from anticholinergic medications for 4 weeks prior enrollment in order to be eligible)
  • Impaired mobility or cognition sufficient to preclude following study procedures; MoCA test score <24/30; a clinically-apparent neurological condition
  • Prolapse beyond the hymen
  • Interstitial cystitis
  • Spinal cord injury
Show all 15Show fewer
  • History of pelvic radiation or advanced uterine/bladder cancer
  • Urethral obstruction (uroflow); PVR >200 ml
  • Medical instability
  • Prior UUI treatment with onabotulinum toxin or neuromodulation
  • Drug interaction or expected medication change during the study
  • Conditions requiring IV antibacterial prophylaxis
  • New incontinence treatment < 3 months prior to enrollment
  • Fecal incontinence, and symptomatic colitis/IBS
  • Contraindications to MRI.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213

Other trials in United States

About this study

This is a randomized double-blind crossover trial of trospium and placebo in women with urgency urinary incontinence, with evaluation (history, physical, incontinence evaluation and brain MRI) at baseline, and after each course of therapy. The investigators will evaluate functional brain changes in relation to bladder improvement in order to improve our knowledge of the brain's role in the continence mechanism.

Read the detailed description

Urgency urinary incontinence (UUI) costs the US $83 billion/year, owing in large part to its increased prevalence with age, particularly in women: 9% of those over age 18 and 36% of those over age 65. UUI also impairs quality of life, social interaction, and independence; contributes to functional decline; and increases risk for falls, hip fractures, UTIs, urosepsis, anxiety, depression, and institutionalization.The cause of UUI is unknown. Its urgency and leakage are usually ascribed to detrusor overactivity (DO, involuntary detrusor contraction), suggesting that the cause is intrinsic to the bladder even though DO is not always confirmed on testing. Because of this assumption, most therapies target the bladder albeit with only moderate success: e.g., anticholinergics reduce incontinence episodes but their benefit and tolerability (especially for older adults) are sufficiently low that 75% of patients discontinue them within a year. By contrast, therapies such as biofeedback-assisted pelvic muscle therapy (BFB) tackle behaviors. Moreover, the use of biofeedback to retrain the brain shows that the central control mechanism can be targeted and improved. Thus, the present proposal is designed to further elucidate this mechanism, thereby paving the way for discovery of new and more effective ways to control UUI. These could transform current treatment and either complement or supplant current therapy.

Explanation for change in study outcomes: This study was designed as a mechanistic study, using the study drug as a probe, to develop a more comprehensive qualitative model of the brain's role in bladder control. We present the primary outcome of response to drug/placebo as a cross-over drug study which allows evaluation of the study drug in a clinical population, as reported in our IRB approval document STUDY19090167. The synthesis of the groups of responders and non-responders to drug or placebo is crucial to allow in depth analysis of changes in brain structure and function which will provide insight into how the brain controls the bladder. However, such analysis is necessarily qualitative, complex and challenging to convey in a context-free numerical format, such as this site. Thus, the initially entered primary outcomes of brain structure and function will be reported with full context in upcoming manuscripts.

Being tested
Trospium, Placebo oral tablet
Keywords
Urinary Incontinence, Urgency urinary incontinence, Trospium
Medical subject headings
Urinary Incontinence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TrospiumDrug

    Also called Sanctura

    Drug to treat overactive bladder

  • Placebo oral tabletDrug

    Also called Placebo

    Placebo tablet containing no active drug

Study groups in NCT04227184
Study groupRoleWhat they receive
Placebo/TrospiumExperimentalPlacebo first for 12 weeks followed by Trospium for 12 weeks.
Receives: Drug: Trospium; Drug: Placebo oral tablet
Trospium/PlaceboExperimentalTrospium first for 12 weeks followed by Placebo for 12 weeks
Receives: Drug: Trospium; Drug: Placebo oral tablet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Responder (Yes/no)

    Whether reduction in number of leaks on 3-day bladder diary is at least 50%

    Measured: Baseline to 12 weeks and baseline to 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2020
  2. Study start13 Feb 2020
  3. Primary completion28 Feb 2025
  4. Study completion30 Oct 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
168 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04227184
Sponsor's protocol ID
STUDY19090167
Other IDs
R01AG064251
Status last verified
Nov 2025
First submitted
9 Jan 2020
Last updated
24 Apr 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: All of the individual participant data collected during the trial, after de-identification may be shared with other researchers.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in